Actively Recruiting

Phase 3
Age: 18Years - 65Years
All Genders
NCT05931263

A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL

Led by The First Affiliated Hospital with Nanjing Medical University · Updated on 2023-07-05

104

Participants Needed

1

Research Sites

243 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this clinical trial is to compare Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL. The main question it aims to answer are: •Whether Chi-BEAM improves patient survival compared to BEAM group Participants will be given BEAM or Chi-BEAM before ASCT. Researchers will compare the efficacy and safety of the two groups.

CONDITIONS

Official Title

A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Pathologically diagnosed newly treated PTCL patients (including NT/K-cell lymphoma), excluding ALK (+), with CR or PR after first-line treatment
  • Kidney function with creatinine clearance 80 ml/min and creatinine less than 160 bcmol/L
  • Liver function: ALT and AST 2 times upper limit of normal; total bilirubin 2 times upper limit of normal
  • Lung function: FEV1, FVC, DLCO 50% predicted value
  • Cardiac function: left ventricular ejection fraction 50%, asymptomatic arrhythmia
  • Age between 18 and 65 years, both male and female
  • ECOG physical strength score of 0-1
  • Neutrophil count 1.5�d7109/L, platelets 70�d7109/L, hemoglobin 90 g/L
  • Number of CD34+ cells 2.0�d7106/kg body weight
  • Expected survival time of at least 3 months
  • Voluntary written informed consent
Not Eligible

You will not qualify if you...

  • Lymphoma involving the central nervous system
  • Active hepatitis B or C virus infection
  • Active infection
  • HIV infection
  • Evidence of cirrhosis or liver fibrosis
  • ECG showing QTc > 500 ms
  • Mental disabilities or inability to provide informed consent
  • Drug or chronic alcohol abuse affecting study evaluation
  • Pregnant or lactating women and women of childbearing potential not using contraception
  • Investigator determination of unsuitability for study participation

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Hematological Department, People's Hospital of Jiangsu Province

Nanjing, Jiangsu, China, 210029

Actively Recruiting

Loading map...

Research Team

W

wei xu

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here